

¹R. Darouiche, I. Raad, S. Heard, J. Thornby, O. Wenker, A. Gabrielli, J. Berg, N. Khardori, H. Hanna, R. Hachem, R. Harris, and G. Mayhall for the Catheter Study Group: "A Comparison of Two Antimicrobial-Impregnated Central Venous Catheters," New England Journal of Medicine, Volume 340, Issue 1, (1999), 1-8.

²I. Raad, R. Darouiche, J. Dupuis, D. Abi-Said, A. Gabrielli, R. Hachem, M. Wall, R. Harris, J. Jones, A. Buzaid, C. Robertson, S. Shenaq, P. Curling, T. Burke, C. Ericsson, Texas Medical Center Catheter Study Group: "Central Venous

Catheters Coated with Minocycline and Rifampin for the Prevention of Catheter-Related Colonization and Bloodstream Infections: A Randomized, Double-Blind Trial," Annals of Internal Medicine, 127 (1997), 267-274.

³D. Pittet, R. Wenzel: "Nosocomial Bloodstream Infections in the Critically III, Letter to the Editor," Journal of the American Medical Association, 272 (1994), 1819-1820.

To learn how Cook Spectrum® can reduce infection rates in vascular access patients and significantly lower treatment costs, contact your (COOK CRITICAL CARE representative. Or call COOK at 1-800 457-4500.

An extensive new study just published in *The New England Journal of Medicine* concludes that catheters impregnated with minocycline and rifampin are **twelve times less likely** to cause bloodstream infections than catheters impregnated with chlorhexidine and silver sulfadiazine.

Central venous catheters are vital to patient care, but they are also the leading cause of primary nosocomial bloodstream infection.²

A single episode of catheter-related septicemia can cost up to \$28,000 to treat (and an extra 6.5 days in the ICU).³

Cook Spectrum® antimicrobial central venous catheters are impregnated throughout their inner and outer surfaces with an effective combination of minocycline and rifampin to fight bacterial colonization and infections.

LISTEN. UNDERSTAND. INNOVATE.

www.cookgroup.com

C COPYRIGHT COOK CRITICAL CARE 1999